• Users Online: 374
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 8  |  Issue : 2  |  Page : 66-72

A retrospective analysis of real-world data to evaluate the safety and effectiveness of topical amorolfine in tinea infection


1 Prathama Skin and Hair Care Center, Virar, Maharashtra, India
2 Skin Care Center, Gandhinagar, Ghaziabad, Uttar Pradesh, India
3 Fortis Hospital, Anandapur & Wizderm Skin & Hair Clinics, Kolkata, West Bengal, India
4 Sardar Smarak Hospital & Muslim Trust Hospital, Surat, Gujarat, India
5 Dermacure Advanced Skin and Hair Clinic, Mayur Vihar, Delhi, India
6 Anagha Skin and Hair Clinic, Bagalkot, Karnataka, India
7 Maganti Hospital, Gudivada, Andhra Pradesh, India
8 Sadar Hospital, Jamuhar, Bihar, India
9 Medical Affairs Department, Zydus Healthcare Ltd., Mumbai, Maharashtra, India

Correspondence Address:
Bhagyashree Mohod
Medical Affairs Department, Zydus Healthcare, ‘Zydus Tower’ CTS No. 460/6,Village Pahadi, Off I. B. Patel Road, Goregaon East, Mumbai 400063, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdd.ijdd_8_22

Rights and Permissions

Background: Conventional antifungals are becoming resistant against dermatophytosis due to development of recalcitrant tinea. These patients may get benefit from newer topical antifungals or combination therapy. Topical antifungal therapy is the mainstay in the treatment of dermatophytosis. Aims/Objectives: To evaluate the safety and effectiveness of topical amorolfine in tinea infection in real-world settings. Materials and Methods: This was a real-world retrospective study; data was collected from 106 centers across India on the usage of amorolfine in the management of tinea infections. The treatment response was evaluated at the end of 2 and 4 week. It was determined by the reduction in severity of the classic symptoms of disease viz. pruritus, burning sensation, erythema, and scaling and crusting at Week 2 and Week 4 of treatment. The severity of symptoms was classified and quantified as mild (1), moderate (2), and severe (3). Safety was determined based on the occurrence of any adverse events during the treatment. Results: An improvement in symptoms score was observed for all the classic symptoms of infection viz. pruritus, burning sensation, erythema, and scaling and crusting at Week 2 and Week 4 compared to baseline. Mean total symptom score (TSS) was reduced to 0.88 ± 1.19 from 7.18 ± 2.84 at week 4 (P < 0.05). Only 10 (0.73%) patients out of 1358 showed mild and non-treatment-related adverse events. Conclusion: Amorolfine alone or in combination therapy with oral antifungals in real world clinical setting represents an improved treatment strategy for patients with tinea infections.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1821    
    Printed127    
    Emailed0    
    PDF Downloaded94    
    Comments [Add]    

Recommend this journal